Dr. Shirish M Gadgeel
Address: 1 Ford Pace, Detroit, Michigan, 48202, United States, Wayne State University
Gender: Male
About the Doctor / Professional
After graduating with his MBBS medical degree from the University of Bombay in Mumbai, India, he completed his Internal Medicine residency in Mumbai. He also completed an internship at LaGuardia Hospital (now Long Island Jewish Forest Hills), as well as his Hematology/Oncology residency and Bone Marrow Transplantation Fellowship at Wayne State University. Following his fellowship, Dr. Gadgeel served as director of the Thoracic Oncology Program and co-leader of Molecular Therapeutics Program at Karmanos Cancer Institute.
Prior to Henry Ford, Dr. Gadgeel was a professor in the Department of Internal Medicine and the Mary Lou Kennedy Research Professor in Thoracic Oncology at the University of Michigan/Michigan Medicine.
Dr. Gadgeel enhances our academic mission through clinical trials and research, while promoting the growth and expansion of clinical services locally, regionally, and nationally -- further positioning Henry Ford Cancer Institute as a destination and referral center for cancer care. He is the principle investigator on numerous clinical trials, and has published extensively in peer-reviewed literature.
Degree: Grant Medical College Univ of Mumbai 1992
Residency: Long Island Jewish Medical Center, Interna Medicine, NY, 1994
- s clinical research experience spans 20 years. He is also a member of the steering committee of the Lung Cancer Committee of Southwest Oncology Group. He is the Associate Editor of Clinical Lung Cancer and a reviewer for many journals, including Clinical Cancer Research, Journal of Clinical Oncology, Lancet Oncology, and Journal of Thoracic Oncology. He has served as faculty for the annual meeting of the American Society of Clinical Oncology (ASCO) and as a member of the education committee of ASCO. He is a member of the Communications committee of the International Association of Study of Lung Cancer (IASLC). He was awarded by the National Cancer Institute the Cancer Clinical Investigator Team Leadership Award in 2012.
- He was awarded by the National Cancer Institute the Cancer Clinical Investigator Team Leadership Award in 2012.
- Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
- Molecular therapeutic targets in non-small cell lung cancer.
- Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic.
- Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
- COPD-dependent effects of genetic variation in key inflammation pathway genes on lung cancer risk.
- Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.
- Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
- Circulating microRNAs as biomarkers of radiation-induced cardiac toxicity in non-small-cell lung cancer.
- Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
- ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
- Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.
- Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.
- Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation.
- Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
- Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors.
- Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
- Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
- Immune Checkpoint Inhibitors in the Management of Lung Cancer.
- Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
- New onset myasthenia gravis in a patient with non small cell lung cancer treated with lorlatinib a novel anti-cancer agent.
- Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.
- Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.
- Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).
- The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
- Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.
- Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results (SEER) Data.
- Retreatment With Osimertinib Following Pneumonitis.
- Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy.
- Role of Chemotherapy and Targeted Therapy in Early-Stage Non-Small Cell Lung Cancer.
- Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer.
- Histologic Transformation in NSCLC with PD-1 therapy.
- Optimal front-line ALK (anaplastic lymphoma kinase) directed therapy.
- Phase II Trial of Dose-dense Pemetrexed, Gemcitabine, and Bevacizumab in Patients With Advanced, Non-Small-cell Lung Cancer.
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
- Preoperative pulmonary rehabilitation for marginal-function lung cancer patients.
- Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.
- Drug selection for anaplastic lymphoma kinase-positive non-small-cell lung cancer.
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
- Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer.
- Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.
- Risk of Lung Cancer Associated with COPD Phenotype Based on Quantitative Image Analysis.
- Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management. Preface.
- Risk of brain metastases in patients with nonmetastatic lung cancer: Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data.
- Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
- Whole-exome sequencing reveals genetic variability among lung cancer cases subphenotyped for emphysema.
- Personalized Therapy of Non-small Cell Lung Cancer (NSCLC).
- Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
- Cyclooxygenase 2 inhibition in patients with non-small cell lung cancer: Is this still a valid target for therapy?
- Rociletinib in EGFR-mutated non-small-cell lung cancer.
- Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study.
- Racial diversity of actionable mutations in non-small cell lung cancer.
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
- Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer.
- A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
- Prognostic and predictive markers for personalized adjuvant therapy for non-small-cell lung cancer patients.
- Fibroblast growth factor receptor 1 amplification in non-small cell lung cancer by quantitative real-time PCR.
- Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.
- Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.
- Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer.
- New targets in non-small cell lung cancer.
- Erlotinib resistance in lung cancer: current progress and future perspectives.
- Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
- Modern staging of small cell lung cancer.
- Treatment of lung cancer.
- Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.
- Soy isoflavones radiosensitize lung cancer while mitigating normal tissue injury.
- Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer.
- XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
- Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.
- Crizotinib: an anaplastic lymphoma kinase inhibitor.
- Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trials.
- Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
- The optimal chemotherapy for stage III non-small cell lung cancer patients.
- Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
- Hope and realism: the perfect balance?
- Soy isoflavones augment radiation effect by inhibiting APE1/Ref-1 DNA repair activity in non-small cell lung cancer.
- Parameters for individualizing systemic therapy in non-small cell lung cancer.
- Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.
- A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.
- Subdividing NSCLC: reflections on the past, present, and future of lung cancer therapy.
- Adjuvant therapy for resected non-small cell lung cancer.
- Patterns of care in a population-based sample of soft tissue sarcoma patients in the United States.
- Targeted therapy in lung cancer: the good, the bad, and the ugly.
- Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.
- Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer.
- Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.
- Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer.
- Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
- Retrospective review of cancer patients > or =80 years old treated with chemotherapy at a comprehensive cancer center.
- Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors.
- Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.
- Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
- Adjuvant treatment of non-small-cell lung cancer: how do we improve the cure rates further?
- Smoking history: tumor biology and clinical pharmacokinetic implications in patients with lung cancer.
- Predictors of enrollment in lung cancer clinical trials.
- Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design.
- Novel combinations using pemetrexed in malignant mesothelioma.
- Racial differences in lung cancer.
- Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer.
- Biochemotherapy of melanoma.
- Bone Marrow Transplant
- Cancer/Oncology Consultation
- Clinical Trials
- Hematology
- Lung Cancer Treatment
- Medical Oncology
- Thoracic Oncology
- Lung Cancer Committee of Southwest Oncology Group
- American Society of Clinical Oncology (ASCO)
- International Association of Study of Lung Cancer (IASLC)